NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

"getting as much tumor into lysate as possible is critical because targets are not evenly distributed in the tumor."
---------------------------------------------

I don't remember this being said but I will take your word for it. Sounds believable, but unfortunate that the distribution could be on a macro scale.
---------------------------------------------
"More recently UCLA has found a way to identify mesenchymal GBM by way of imaging so tumor loss for identification of this subtype is no longer required. Best wishes."
----------------------------------------------

They must have had some method by the 2014 trial changes PR that Longfellow reposted a few posts up the page today. A method sufficient to allow "Control". Either balancing patient types or accounting for the difference in post analysis.

Thanks for the info Doc and I will cross my fingers that the Mesenchymal MRI analysis is being allowed in the data analysis that has happened, is happening, or will soon be happening. Of course the whole ball of wax would be preferred over a subgroup approval, with the hope and expectation that it would be the start down the correct path.